The rapidly changing epidemiology of duodenal ulcer during this century' points to an extrinsic factor as a possible cause of the disease, and 30 years ago it was proposed that infection with herpes simplex virus might be involved in the pathogenesis.2 Since then this hypothesis has been supported by demonstration of herpes simplex virus in human vagal ganglia3 and the finding of significantly higher titres of anti herpes simplex type 1 antibodies in patients with duodenal ulcer than in seropositive control individuals.4 Herpes simplex virus has also been found in the gastric mucosa, but only in patients being treated with immunosuppressive agents.5
The rapidly changing epidemiology of duodenal ulcer during this century' points to an extrinsic factor as a possible cause of the disease, and 30 years ago it was proposed that infection with herpes simplex virus might be involved in the pathogenesis.2 Since then this hypothesis has been supported by demonstration of herpes simplex virus in human vagal ganglia3 and the finding of significantly higher titres of anti herpes simplex type 1 antibodies in patients with duodenal ulcer than in seropositive control individuals. 4 Herpes simplex virus has also been found in the gastric mucosa, but only in patients being treated with immunosuppressive agents. 5 As acyclovir was shown to be safe and effective in the prophylaxis against reactivation of herpes simplex virus"9 we decided to use this drug to test the hypothesis that herpes virus is responsible for recurrent duodenal ulceration. allocated at random to take trial tablets containing either acyclovir 400 mg or placebo, one to be taken in the morning and one in the evening for 25 weeks. The patients were seen at five week intervals for clinical assessment and a tablet compliance count.
The patients contacted the clinic if ulcer symptoms recurred on three or more days within the same week, and an upper gastrointestinal endoscopy was then performed.
Treatment was stopped if duodenal ulcer recurrence was verified at endoscopy. All patients who completed the 25 week study without symptomatic ulcer recurrence were endoscoped at the end of the study. Patients who missed taking tablets for more than three days during a five week period and patients who developed a gastric ulcer without a simultaneous duodenal ulcer were withdrawn.
The efficacy variable was endoscopic recurrence of a duodenal ulcer and the data were subjected to both a 'per protocol analysis' -that is, including only patients who completed the study according to the protocol, and an 'intention to treat' analysis -that is, including all patients who entered the study, and considering all patients who were withdrawn as treatment failures -namely, those having relapsed.
Results
One hundred and fifteen patients entered the study and the treatment groups were found to be comparable. Details are shown in Table I blocker was given; five patients did not attend at scheduled visits; four patients developed a gastric ulcer and one patient an oesophageal ulcer; and three patients wanted to leave the study. The cumulative recurrence rate of duodenal ulcer after 25 weeks was 63% in the acyclovir group and 56% in the placebo group (standard error ofdifference= 11 0%), Table II . The 'intention to treat' cohort showed a similar result with 76% and 70% relapses in the acyclovir and placebo group respectively. The time of recurrence did not differ between the two groups ( Figure) . Only one asymptomatic ulcer was found at endoscopy at 25 weeks. Fourteen patients (six acyclovir, eight placebo) developed symptomatic relapse with no demonstrable ulcer at endoscopy.
No side-effects were recorded. One of the arguments in favour of the hypothesis was that duodenal ulcer patients were found to have higher antiherpes virus antibody titres in their serum than matched controls. 4 The immune response to a chronic viral infection such as herpes is, however, regulated in a highly complex fashion involving many elements."' Raised antibody titres to herpes simplex virus may therefore be explained by a non-specific hyper-responsiveness of ulcer patients and not necessarily by activation of the virus. This explanation is supported by the finding that ulcer patients also have higher titres of antibodies against rubella virus. "
Discussion

